🇺🇸 FDA
Patent

US 7824681

Human monoclonal antibodies that specifically bind IGF-II

granted A61KA61K2039/505A61P

Quick answer

US patent 7824681 (Human monoclonal antibodies that specifically bind IGF-II) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Oct 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Nov 02 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K2039/505, A61P, A61P43/00